<DOC>
	<DOCNO>NCT02025621</DOCNO>
	<brief_summary>A study evaluate levosimendan compare placebo reduce composite event rate all-cause death , perioperative MI , need new dialysis , use mechanical assist ( IABP , LVAD ECMO ) subject reduced ejection fraction undergo cardiac surgery cardiopulmonary bypass ( CPB ) .</brief_summary>
	<brief_title>Levosimendan Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass</brief_title>
	<detailed_description>This study do evaluate efficacy levosimendan compare placebo reduce co-primary endpoint 30-day composite all-cause death use mechanical assist device ( IABP , LVAD ECMO ) composite event rate all-cause death , perioperative MI , need dialysis , use mechanical assist ( IABP , LVAD ECMO ) subject reduced ejection fraction undergo cardiac surgery CPB .</detailed_description>
	<mesh_term>Cardiac Output , Low</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>Documented LVEF ≤35 % measure ventriculogram , echocardiogram ( ECHO ) , nuclear scan , MRI within 60 day surgery . Scheduled urgent 1 ) CABG surgery , 2 ) CABG aortic valve surgery , 3 ) CABG mitral valve surgery , 4 ) mitral valve surgery without valve Surgery employ CPB pump Signed ( subject legally acceptable representative ) inform consent document indicate understand purpose procedure require study willing participate study Restrictive obstructive cardiomyopathy , constrictive pericarditis , restrictive pericarditis , pericardial tamponade , condition cardiac output dependent venous return . Evidence systemic bacterial , systemic fungal , viral infection within 72 hour surgery . Dialysis randomization ( either hemodialysis , peritoneal dialysis , continuous venovenous hemofiltration , ultrafilitration ) . Estimated glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73m2 . Weight ≥ 170 kg . Patients whose SBP manage ensure SBP &gt; 90 mmHg initiation study drug . Heart rate ≥ 120 bpm , persistent least 10 minute screen unresponsive treatment . Hemoglobin &lt; 80 g/L . Serum potassium &lt; 3.5 mmol/L &gt; 5.5 mmol/L baseline . A history Torsades de Pointes . Mechanical assist device ( IABP , LVAD , ECMO ) patient start surgery preplanned inserted surgery come CPB . Patients aortal femoral occlusive disease would prohibit use IABP unless VAD ECMO available . Liver dysfunction Child Pugh Class B C Patients severely compromise immune function Pregnant , suspect pregnant , breastfeed . Received experimental drug use experimental medical device previous 30 day . Known allergic reaction sensitivity Levosimendan excipients . Received commercial Levosimendan within 30 day plan start study drug . Employees investigator study center , direct involvement propose study study direction investigator study center , well family member employee investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>coronary artery bypass grafting</keyword>
	<keyword>CABG</keyword>
	<keyword>mitral valve</keyword>
	<keyword>LCOS</keyword>
	<keyword>low cardiac output syndrome</keyword>
	<keyword>levosimendan</keyword>
</DOC>